Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract

  • Technology appraisal guidance
  • TA272
  • Published: 

Transitional cell carcinoma of the urothelial tract - vinflunine: appeal announcement

The Institute has received one appeal from Pierre Fabre Ltd.

The Appeal hearing took place at NICE, Level 1a City Tower, Piccadilly Plaza, Manchester M1 4BD on Monday 23 May 2011at 11am.

The Institute awaits the decision of the Appeal Panel.

This page was last updated: 18 May 2011